glp 1 in non diabetic Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? GLP-1 use tripled among non-diabetics,
Description
Ben Nasr, M
Here is the time-to-event analysis which again shows the non-fatal heart attack (MI) reduction, whereas nonfatal stroke was not significantly reduced (a 7% relative reduction)
The study concluded that semaglutide, even at relatively low doses, may help control HS by reducing weight and improving patients quality of life, though its effect on inflammatory markers and flare frequency was less pronounced
Neurochem Int
Group for research and assessment of psoriasis and psoriatic arthritis (Grappa): Updated treatment recommendations for psoriatic arthritis 2021
